Arron Lacey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arron Lacey has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- William Owen Pickrell
Swansea University
11 shared publications - Ronan Anthony Lyons
Population Data Science, Swansea University Medical School, Swansea, UK
7 shared publications - Ashley Akbari
Population Data Science, Swansea University Medical School, Swansea University, Swansea, UK
6 shared publications Beata Fonferko-Shadrach
Health Data Research UK, Swansea University Medical School, Swansea University, Swansea, United Kingdom
5 shared publications- Majd B. Protty
Cardiff University
5 shared publications - Mark I. Rees
Institute of Life Science, College of Medicine, Swansea University, Swansea SA2 8PP, United Kingdom
4 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Duodenal involvement in MUTYH-associated polyposis: findings from an international study and implications for endoscopic surveillance.
Objectives: This study aimed to better document incidence and progression of duodenal disease in MUTYH -associated polyposis (MAP). Methods: Incidences of duodenal cancer, and duodenal polyposis by age and genotype were assessed in individuals with genetically confirmed MAP. Results: At first endoscopy, 91/679 participants (13.4%) had duodenal adenoma(s) at a median age of 53 years (range 22 to 81 years). 439/679 participants had 1370 further endoscopies, over a median period of 6.3 years (range 1 month to 30 years). This included 365 without adenomas at first endoscopy, of whom 83 (22.7%) developed non-ampullary adenomas during follow-up at a median age of 53 years (range 29-76). Thirty-eight adenomas (5.5%) contained high-grade dysplasia (HGD), of which thirty-five had a known size and 20 (57.1%) of these were 10mm or smaller. Ampullary lesions were uncommon (31/679, 4.6%). Duodenal cancer was diagnosed in 5/679 participants (0.74%) at a median age of 65 years (range 47-83 years) and at a median of 12 months (range 9-24 months) following a surveillance endoscopy. At least four were located distally (in the third or fourth part). The cumulative incidences of duodenal adenomas and cancer at 70 years were 16.5-63.5%, depending on genotype, and 0.58%, respectively. Adenoma incidence was significantly higher in Y179C (hazard ratio 5.33 (2.94–9.67, <0.001) and E480X (4.07 (2.16–7.67), <0.001) than G396D homozygotes. Conclusions: Future clinical guidelines for MAP should consider genotype-specific recommendations for duodenal surveillance, the importance of assessing the distal duodenum (i.e. D3, D4) and polypectomy of all detectable adenomas.
- 13 October 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Duodenal involvement in MUTYH-associated polyposis: findings from an international study and implications for endoscopic surveillance.
Objectives: This study aimed to better document incidence and progression of duodenal disease in MUTYH -associated polyposis (MAP). Methods: Incidences of duodenal cancer, and duodenal polyposis by age and genotype were assessed in individuals with genetically confirmed MAP. Results: At first endoscopy, 91/679 participants (13.4%) had duodenal adenoma(s) at a median age of 53 years (range 22 to 81 years). 439/679 participants had 1370 further endoscopies, over a median period of 6.3 years (range 1 month to 30 years). This included 365 without adenomas at first endoscopy, of whom 83 (22.7%) developed non-ampullary adenomas during follow-up at a median age of 53 years (range 29-76). Thirty-eight adenomas (5.5%) contained high-grade dysplasia (HGD), of which thirty-five had a known size and 20 (57.1%) of these were 10mm or smaller. Ampullary lesions were uncommon (31/679, 4.6%). Duodenal cancer was diagnosed in 5/679 participants (0.74%) at a median age of 65 years (range 47-83 years) and at a median of 12 months (range 9-24 months) following a surveillance endoscopy. At least four were located distally (in the third or fourth part). The cumulative incidences of duodenal adenomas and cancer at 70 years were 16.5-63.5%, depending on genotype, and 0.58%, respectively. Adenoma incidence was significantly higher in Y179C (hazard ratio 5.33 (2.94–9.67, <0.001) and E480X (4.07 (2.16–7.67), <0.001) than G396D homozygotes. Conclusions: Future clinical guidelines for MAP should consider genotype-specific recommendations for duodenal surveillance, the importance of assessing the distal duodenum (i.e. D3, D4) and polypectomy of all detectable adenomas.
- Open Access
- 17 April 2026
- Published by SAGE Publications in Journal of Child Neurology
Paediatric Idiopathic Intracranial Hypertension in Wales: A Retrospective Observational Study
This study measures the incidence and prevalence of idiopathic intracranial hypertension (IIH) in children in Wales and assesses risk factors and health care utilisation. We identified 177 children (1-15 years) with IIH diagnosed between 2003 and 2017. Incidence increased from 1.6/100 000 per year (2003) to 3.5/100 000 per year (2017). Sixty-three percent of the cases were girls, and 87% were diagnosed between 7 and 15 years. Children in the most deprived quintile were more likely to develop IIH compared to children in the least deprived quintile (odds ratio [OR] = 1.7 [95%CI = 1.1-2.9]). Obese and overweight children were more likely to develop IIH compared with non-overweight children (ORs = 21 [95%CI = 9-51] and 5.1 [95%CI = 1.9-14]). Children with IIH had higher hospital admission rates than children without IIH (rate ratio = 3.9; 95% CI 3.6-4.3). The increasing incidence, association with BMI and deprivation, and increased health care utilisation in children with IIH are relevant findings to health care professionals and policy makers.
- 17 April 2026
- Published by SAGE Publications in Journal of Child Neurology
Open AccessPaediatric Idiopathic Intracranial Hypertension in Wales: A Retrospective Observational Study
This study measures the incidence and prevalence of idiopathic intracranial hypertension (IIH) in children in Wales and assesses risk factors and health care utilisation. We identified 177 children (1-15 years) with IIH diagnosed between 2003 and 2017. Incidence increased from 1.6/100 000 per year (2003) to 3.5/100 000 per year (2017). Sixty-three percent of the cases were girls, and 87% were diagnosed between 7 and 15 years. Children in the most deprived quintile were more likely to develop IIH compared to children in the least deprived quintile (odds ratio [OR] = 1.7 [95%CI = 1.1-2.9]). Obese and overweight children were more likely to develop IIH compared with non-overweight children (ORs = 21 [95%CI = 9-51] and 5.1 [95%CI = 1.9-14]). Children with IIH had higher hospital admission rates than children without IIH (rate ratio = 3.9; 95% CI 3.6-4.3). The increasing incidence, association with BMI and deprivation, and increased health care utilisation in children with IIH are relevant findings to health care professionals and policy makers.
- Open Access
- 8 November 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 134-138
Educational attainment of children with self-limited epilepsy with CentroTemporal spikes (SELECTS), other epilepsies, and without epilepsy: A retrospective cohort study
- 8 November 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 134-138
Open AccessEducational attainment of children with self-limited epilepsy with CentroTemporal spikes (SELECTS), other epilepsies, and without epilepsy: A retrospective cohort study
- Open Access
- 30 October 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (11) , 1649
The Environmental Consequence of Early Colorectal Cancer Detection: A Literature Review of the Environmental Impact Assessment of Colorectal Cancer Diagnostic Pathways
Background: Colorectal cancer (CRC) is a burden to healthcare globally, with early detection vital to improving outcomes. While screening and early diagnostic strategies are being widely implemented, their environmental impact remains underexplored. The purpose of this literature review is to examine the existing research on the environmental footprint of non-emergency sporadic CRC diagnostic pathways and provide an overview of environmental impact assessment processes. Principal findings: Population-based screening appears environmentally beneficial over time, but its efficiency critically determines its net impact. Studies identify endoscopy as having the highest environmental impact among testing modalities. The dominant contributor to this is patient and staff travel. By contrast, faecal-based tests appear to have the lowest environmental footprint. Notably, pathway-wide assessments are limited, and methodological inconsistencies hinder comparing studies. Conclusions: There is an urgent need to standardise a healthcare sector-specific framework for environmental impact assessments. Emerging biomarker-based diagnostics will require a robust pathway-wide environmental impact assessment before clinical integration.
- 30 October 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (11) , 1649
Open AccessThe Environmental Consequence of Early Colorectal Cancer Detection: A Literature Review of the Environmental Impact Assessment of Colorectal Cancer Diagnostic Pathways
Background: Colorectal cancer (CRC) is a burden to healthcare globally, with early detection vital to improving outcomes. While screening and early diagnostic strategies are being widely implemented, their environmental impact remains underexplored. The purpose of this literature review is to examine the existing research on the environmental footprint of non-emergency sporadic CRC diagnostic pathways and provide an overview of environmental impact assessment processes. Principal findings: Population-based screening appears environmentally beneficial over time, but its efficiency critically determines its net impact. Studies identify endoscopy as having the highest environmental impact among testing modalities. The dominant contributor to this is patient and staff travel. By contrast, faecal-based tests appear to have the lowest environmental footprint. Notably, pathway-wide assessments are limited, and methodological inconsistencies hinder comparing studies. Conclusions: There is an urgent need to standardise a healthcare sector-specific framework for environmental impact assessments. Emerging biomarker-based diagnostics will require a robust pathway-wide environmental impact assessment before clinical integration.
- Open Access
- 15 July 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 69, 241-256
Investigating the effects of probiotics during the menopause transition: A systematic review & meta-analysis
- 15 July 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 69, 241-256
Open AccessInvestigating the effects of probiotics during the menopause transition: A systematic review & meta-analysis
- Open Access
- 11 September 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 122, 52-57
Epidemiology of self-limited epilepsy with centrotemporal spikes (SeLECTS): A population study using primary care records
- 11 September 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 122, 52-57
Open AccessEpidemiology of self-limited epilepsy with centrotemporal spikes (SeLECTS): A population study using primary care records
- Open Access
Health care utilization and mortality for people with epilepsy during COVID‐19: A population study
Objective: This study was undertaken to characterize changes in health care utilization and mortality for people with epilepsy (PWE) during the COVID‐19 pandemic.Methods: We performed a retrospective study using linked, individual‐level, population‐scale anonymized health data from the Secure Anonymised Information Linkage databank. We identified PWE living in Wales during the study “pandemic period” (January 1, 2020–June 30, 2021) and during a “prepandemic” period (January 1, 2016–December 31, 2019). We compared prepandemic health care utilization, status epilepticus, and mortality rates with corresponding pandemic rates for PWE and people without epilepsy (PWOE). We performed subgroup analyses on children (65 years old), those with intellectual disability, and those living in the most deprived areas. We used Poisson models to calculate adjusted rate ratios (RRs).Results: We identified 27 279 PWE who had significantly higher rates of hospital (50.3 visits/1000 patient months), emergency department (55.7), and outpatient attendance (172.4) when compared to PWOE (corresponding figures: 25.7, 25.2, and 87.0) in the prepandemic period. Hospital and epilepsy‐related hospital admissions, and emergency department and outpatient attendances all reduced significantly for PWE (and all subgroups) during the pandemic period. RRs [95% confidence intervals (CIs)] for pandemic versus prepandemic periods were .70 [.69–.72], .77 [.73–.81], .78 [.77–.79], and .80 [.79–.81]. The corresponding rates also reduced for PWOE. New epilepsy diagnosis rates decreased during the pandemic compared with the prepandemic period (2.3/100 000/month cf. 3.1/100 000/month, RR = .73, 95% CI = .68–.78). Both all‐cause deaths and deaths with epilepsy recorded on the death certificate increased for PWE during the pandemic (RR = 1.07, 95% CI = .997–1.145 and RR = 2.44, 95% CI = 2.12–2.81). When removing COVID deaths, RRs were .88 (95% CI = .81–.95) and 1.29 (95% CI = 1.08–1.53). Status epilepticus rates did not change significantly during the pandemic (RR = .95, 95% CI = .78–1.15).Significance: All‐cause non‐COVID deaths did not increase but non‐COVID deaths associated with epilepsy did increase for PWE during the COVID‐19 pandemic. The longer term effects of the decrease in new epilepsy diagnoses and health care utilization and increase in deaths associated with epilepsy need further research.
Open AccessHealth care utilization and mortality for people with epilepsy during COVID‐19: A population study
Objective: This study was undertaken to characterize changes in health care utilization and mortality for people with epilepsy (PWE) during the COVID‐19 pandemic.Methods: We performed a retrospective study using linked, individual‐level, population‐scale anonymized health data from the Secure Anonymised Information Linkage databank. We identified PWE living in Wales during the study “pandemic period” (January 1, 2020–June 30, 2021) and during a “prepandemic” period (January 1, 2016–December 31, 2019). We compared prepandemic health care utilization, status epilepticus, and mortality rates with corresponding pandemic rates for PWE and people without epilepsy (PWOE). We performed subgroup analyses on children (65 years old), those with intellectual disability, and those living in the most deprived areas. We used Poisson models to calculate adjusted rate ratios (RRs).Results: We identified 27 279 PWE who had significantly higher rates of hospital (50.3 visits/1000 patient months), emergency department (55.7), and outpatient attendance (172.4) when compared to PWOE (corresponding figures: 25.7, 25.2, and 87.0) in the prepandemic period. Hospital and epilepsy‐related hospital admissions, and emergency department and outpatient attendances all reduced significantly for PWE (and all subgroups) during the pandemic period. RRs [95% confidence intervals (CIs)] for pandemic versus prepandemic periods were .70 [.69–.72], .77 [.73–.81], .78 [.77–.79], and .80 [.79–.81]. The corresponding rates also reduced for PWOE. New epilepsy diagnosis rates decreased during the pandemic compared with the prepandemic period (2.3/100 000/month cf. 3.1/100 000/month, RR = .73, 95% CI = .68–.78). Both all‐cause deaths and deaths with epilepsy recorded on the death certificate increased for PWE during the pandemic (RR = 1.07, 95% CI = .997–1.145 and RR = 2.44, 95% CI = 2.12–2.81). When removing COVID deaths, RRs were .88 (95% CI = .81–.95) and 1.29 (95% CI = 1.08–1.53). Status epilepticus rates did not change significantly during the pandemic (RR = .95, 95% CI = .78–1.15).Significance: All‐cause non‐COVID deaths did not increase but non‐COVID deaths associated with epilepsy did increase for PWE during the COVID‐19 pandemic. The longer term effects of the decrease in new epilepsy diagnoses and health care utilization and increase in deaths associated with epilepsy need further research.
- Open Access
Epilepsy and the risk of COVID‐19‐related hospitalization and death: A population study
Objective: People with epilepsy (PWE) may be at an increased risk of severe COVID-19. It is important to characterize this risk to inform PWE and for future health and care planning. We assessed whether PWE were at higher risk of being hospitalized with, or dying from, COVID-19. Methods: We performed a retrospective cohort study using linked, population-scale, anonymized electronic health records from the SAIL (Secure Anonymised Information Linkage) databank. This includes hospital admission and demographic data for the complete Welsh population (3.1 million) and primary care records for 86% of the population. We identified 27 279 PWE living in Wales during the study period (March 1, 2020 to June 30, 2021). Controls were identified using exact 5:1 matching (sex, age, and socioeconomic status). We defined COVID-19 deaths as having International Classification of Diseases, 10th Revision (ICD-10) codes for COVID-19 on death certificates or occurring within 28 days of a positive SARS-CoV-2 polymerase chain reaction (PCR) test. COVID-19 hospitalizations were defined as having a COVID-19 ICD-10 code for the reason for admission or occurring within 28 days of a positive SARS-CoV-2 PCR test. We recorded COVID-19 vaccinations and comorbidities known to increase the risk of COVID-19 hospitalization and death. We used Cox proportional hazard models to calculate hazard ratios. Results: There were 158 (.58%) COVID-19 deaths and 933 (3.4%) COVID-19 hospitalizations in PWE, and 370 (.27%) deaths and 1871 (1.4%) hospitalizations in controls. Hazard ratios for COVID-19 death and hospitalization in PWE compared to controls were 2.15 (95% confidence interval [CI] = 1.78-2.59) and 2.15 (95% CI = 1.94-2.37), respectively. Adjusted hazard ratios (adjusted for comorbidities) for death and hospitalization were 1.32 (95% CI = 1.08-1.62) and 1.60 (95% CI = 1.44-1.78). Significance: PWE are at increased risk of being hospitalized with, and dying from, COVID-19 when compared to age-, sex-, and deprivation-matched controls, even when adjusting for comorbidities. This may have implications for prioritizing future COVID-19 treatments and vaccinations for PWE.
Open AccessEpilepsy and the risk of COVID‐19‐related hospitalization and death: A population study
Objective: People with epilepsy (PWE) may be at an increased risk of severe COVID-19. It is important to characterize this risk to inform PWE and for future health and care planning. We assessed whether PWE were at higher risk of being hospitalized with, or dying from, COVID-19. Methods: We performed a retrospective cohort study using linked, population-scale, anonymized electronic health records from the SAIL (Secure Anonymised Information Linkage) databank. This includes hospital admission and demographic data for the complete Welsh population (3.1 million) and primary care records for 86% of the population. We identified 27 279 PWE living in Wales during the study period (March 1, 2020 to June 30, 2021). Controls were identified using exact 5:1 matching (sex, age, and socioeconomic status). We defined COVID-19 deaths as having International Classification of Diseases, 10th Revision (ICD-10) codes for COVID-19 on death certificates or occurring within 28 days of a positive SARS-CoV-2 polymerase chain reaction (PCR) test. COVID-19 hospitalizations were defined as having a COVID-19 ICD-10 code for the reason for admission or occurring within 28 days of a positive SARS-CoV-2 PCR test. We recorded COVID-19 vaccinations and comorbidities known to increase the risk of COVID-19 hospitalization and death. We used Cox proportional hazard models to calculate hazard ratios. Results: There were 158 (.58%) COVID-19 deaths and 933 (3.4%) COVID-19 hospitalizations in PWE, and 370 (.27%) deaths and 1871 (1.4%) hospitalizations in controls. Hazard ratios for COVID-19 death and hospitalization in PWE compared to controls were 2.15 (95% confidence interval [CI] = 1.78-2.59) and 2.15 (95% CI = 1.94-2.37), respectively. Adjusted hazard ratios (adjusted for comorbidities) for death and hospitalization were 1.32 (95% CI = 1.08-1.62) and 1.60 (95% CI = 1.44-1.78). Significance: PWE are at increased risk of being hospitalized with, and dying from, COVID-19 when compared to age-, sex-, and deprivation-matched controls, even when adjusting for comorbidities. This may have implications for prioritizing future COVID-19 treatments and vaccinations for PWE.
- Open Access
- 25 February 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (2) , e0264529
Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: Influence of depression and sex
To explore differences in the use of lipid lowering therapy and/or achievement of lipid guideline targets in patients with and without prior depression and influence of sex in very high-risk coronary patients. A retrospective observational cohort study was conducted using individual-level linked electronic health record data in patients who underwent percutaneous coronary intervention (2012–2017) in Wales. The cohort comprised of 13,781 patients (27.4% female), with 26.1% having prior depression. Lipid levels were recorded in 10,050 patients of whom 25% had depression. History of depression was independently associated with not having lipids checked (OR 0.79 95%CI 0.72–0.87 p<0.001). Patients with prior depression were less likely to achieve targets for low density lipoprotein cholesterol (LDL-C <1.8mmol/l), non-high density lipoprotein cholesterol (non-HDL-C <2.6mmol/l) and triglycerides (<2.3mmol/l) than patients without depression (OR 0.86 95%CI 0.78–0.96 p = 0.007, OR 0.80 95%CI 0.69–0.92 p = 0.003 & OR 0.69 95CI% 0.61–0.79 p<0.001 respectively). Females were less likely to achieve targets for LDL-C and non-HDL-C than males (OR 0.55 95%CI 0.50–0.61 p<0.001 & OR 0.63 95%CI 0.55–0.73 p<0.001). There was an additive effect of depression and sex; females with depression were not only least likely to be tested (OR 0.74 95%CI 0.65–0.84 p<0.001) but also (where levels were known) less likely to achieve LDL-C (OR 0.47 95%CI 0.41–0.55 p<0.001) and non-HDL-C targets (OR 0.50 95%CI 0.41–0.60 p<0.001). It was not possible to look at the influence of medication adherence on achievement of lipid targets due to limitations of the use of anonymised routinely-held clinical care data. Patients with prior depression were less likely to have their lipids monitored and achieve guideline targets within 1-year. Females with depression are the least likely to be tested and achieve lipid targets, suggesting not only a greater risk of future events, but also an opportunity to improve care.
- 25 February 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (2) , e0264529
Open AccessAchievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: Influence of depression and sex
To explore differences in the use of lipid lowering therapy and/or achievement of lipid guideline targets in patients with and without prior depression and influence of sex in very high-risk coronary patients. A retrospective observational cohort study was conducted using individual-level linked electronic health record data in patients who underwent percutaneous coronary intervention (2012–2017) in Wales. The cohort comprised of 13,781 patients (27.4% female), with 26.1% having prior depression. Lipid levels were recorded in 10,050 patients of whom 25% had depression. History of depression was independently associated with not having lipids checked (OR 0.79 95%CI 0.72–0.87 p<0.001). Patients with prior depression were less likely to achieve targets for low density lipoprotein cholesterol (LDL-C <1.8mmol/l), non-high density lipoprotein cholesterol (non-HDL-C <2.6mmol/l) and triglycerides (<2.3mmol/l) than patients without depression (OR 0.86 95%CI 0.78–0.96 p = 0.007, OR 0.80 95%CI 0.69–0.92 p = 0.003 & OR 0.69 95CI% 0.61–0.79 p<0.001 respectively). Females were less likely to achieve targets for LDL-C and non-HDL-C than males (OR 0.55 95%CI 0.50–0.61 p<0.001 & OR 0.63 95%CI 0.55–0.73 p<0.001). There was an additive effect of depression and sex; females with depression were not only least likely to be tested (OR 0.74 95%CI 0.65–0.84 p<0.001) but also (where levels were known) less likely to achieve LDL-C (OR 0.47 95%CI 0.41–0.55 p<0.001) and non-HDL-C targets (OR 0.50 95%CI 0.41–0.60 p<0.001). It was not possible to look at the influence of medication adherence on achievement of lipid targets due to limitations of the use of anonymised routinely-held clinical care data. Patients with prior depression were less likely to have their lipids monitored and achieve guideline targets within 1-year. Females with depression are the least likely to be tested and achieve lipid targets, suggesting not only a greater risk of future events, but also an opportunity to improve care.